NO20020779L - Fremgangsmåter, preparater og sett for å fremme helbredelse ved skader på sentralnervesystemet - Google Patents

Fremgangsmåter, preparater og sett for å fremme helbredelse ved skader på sentralnervesystemet

Info

Publication number
NO20020779L
NO20020779L NO20020779A NO20020779A NO20020779L NO 20020779 L NO20020779 L NO 20020779L NO 20020779 A NO20020779 A NO 20020779A NO 20020779 A NO20020779 A NO 20020779A NO 20020779 L NO20020779 L NO 20020779L
Authority
NO
Norway
Prior art keywords
kits
preparations
methods
nervous system
central nervous
Prior art date
Application number
NO20020779A
Other languages
English (en)
Other versions
NO20020779D0 (no
Inventor
Seth P Finkelstein
Evan P Snyder
Original Assignee
Gen Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gen Hospital Corp filed Critical Gen Hospital Corp
Publication of NO20020779D0 publication Critical patent/NO20020779D0/no
Publication of NO20020779L publication Critical patent/NO20020779L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Psychology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO20020779A 1999-08-18 2002-02-15 Fremgangsmåter, preparater og sett for å fremme helbredelse ved skader på sentralnervesystemet NO20020779L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14956199P 1999-08-18 1999-08-18
PCT/US2000/022843 WO2001012236A2 (en) 1999-08-18 2000-08-18 Methods, compositions and kits for promoting recovery from damage to the central nervous system

Publications (2)

Publication Number Publication Date
NO20020779D0 NO20020779D0 (no) 2002-02-15
NO20020779L true NO20020779L (no) 2002-04-15

Family

ID=22530841

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20020779A NO20020779L (no) 1999-08-18 2002-02-15 Fremgangsmåter, preparater og sett for å fremme helbredelse ved skader på sentralnervesystemet

Country Status (10)

Country Link
EP (1) EP1210106A2 (no)
JP (1) JP2003507349A (no)
CN (1) CN1753686A (no)
AU (1) AU6790300A (no)
BR (1) BR0013388A (no)
CA (1) CA2380953A1 (no)
IL (1) IL148175A0 (no)
MX (1) MXPA02001719A (no)
NO (1) NO20020779L (no)
WO (1) WO2001012236A2 (no)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0021668D0 (en) * 2000-09-04 2000-10-18 Smithkline Beecham Plc New use
DE10111486A1 (de) * 2001-03-09 2002-10-02 Ralph R Dawirs Verwendung einer oder mehrerer neuroaktiver Substanzen zur Behandlung der Parkinsonschen Krankheit
GB0117645D0 (en) 2001-07-19 2001-09-12 Isis Innovation Therapeutic stratergies for prevention and treatment of alzheimers disease
US7981863B2 (en) 2001-09-19 2011-07-19 Neuronova Ab Treatment of Parkinson's disease with PDGF
CA2473503C (en) 2002-01-14 2010-01-05 The Board Of Trustees Of The University Of Illinois Use of modified pyrimidine compounds to promote stem cell migration and proliferation
US7432243B2 (en) * 2002-04-08 2008-10-07 The Scripps Research Institute Truncated 24kDa basic fibroblast growth factor
US8118722B2 (en) 2003-03-07 2012-02-21 Neuronetics, Inc. Reducing discomfort caused by electrical stimulation
US7153256B2 (en) 2003-03-07 2006-12-26 Neuronetics, Inc. Reducing discomfort caused by electrical stimulation
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US8093205B2 (en) 2003-12-01 2012-01-10 Medtronic, Inc. Method for treating a stroke by implanting a first therapy delivery element in the CNS and a second therapy delivery element in a damaged tissue of the CNS to promote neurogenesis
US7651459B2 (en) 2004-01-06 2010-01-26 Neuronetics, Inc. Method and apparatus for coil positioning for TMS studies
US8177702B2 (en) 2004-04-15 2012-05-15 Neuronetics, Inc. Method and apparatus for determining the proximity of a TMS coil to a subject's head
US7601115B2 (en) 2004-05-24 2009-10-13 Neuronetics, Inc. Seizure therapy method and apparatus
US20060104969A1 (en) * 2004-08-16 2006-05-18 Massachusetts Institute Of Technology Compositions and methods for enhancing structural and functional nervous system reorganization and recovery
US7857746B2 (en) 2004-10-29 2010-12-28 Nueronetics, Inc. System and method to reduce discomfort using nerve stimulation
US8088058B2 (en) 2005-01-20 2012-01-03 Neuronetics, Inc. Articulating arm
US7396326B2 (en) 2005-05-17 2008-07-08 Neuronetics, Inc. Ferrofluidic cooling and acoustical noise reduction in magnetic stimulators
US7824324B2 (en) 2005-07-27 2010-11-02 Neuronetics, Inc. Magnetic core for medical procedures
US20070135859A1 (en) * 2005-12-09 2007-06-14 Peter Eriksson Use of transcranial magnetic stimulation to improve memory and stress related syndromes in humans
PL2027470T3 (pl) * 2006-06-02 2013-03-29 Pfizer Prod Inc Oznaczenie krążących komórek nowotworowych
DE102007003565B4 (de) 2007-01-24 2012-05-24 Forschungszentrum Jülich GmbH Vorrichtung zur Reduktion der Synchronisation neuronaler Hirnaktivität sowie dafür geeignete Spule
US9884200B2 (en) 2008-03-10 2018-02-06 Neuronetics, Inc. Apparatus for coil positioning for TMS studies
US8791128B2 (en) 2008-09-16 2014-07-29 University Of Central Florida Research Foundation, Inc. Compositions for treating or delaying the onset of hair loss
EP2701727B1 (en) 2011-03-04 2019-05-08 The Regents of The University of California Locally released growth factors to mediate motor recovery after stroke
CN103230581B (zh) * 2011-11-10 2016-12-21 陈锦辉 用于治疗创伤性脑损伤的组合物和方法
CN103421800B (zh) * 2013-09-05 2015-07-22 新乡医学院 用于治疗脊髓损伤的重组基因、重组载体和重组细胞
CN103555747B (zh) * 2013-10-22 2015-04-08 深圳先进技术研究院 胶质细胞bFGF表达提高系统及其构建方法和应用
JP6339737B2 (ja) * 2014-08-15 2018-06-06 ナショナル ヘルス リサーチ インスティテュートス 神経幹細胞とＩＬ１２ｐ４０を使用して神経再生を促進するための組成物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612211A (en) * 1990-06-08 1997-03-18 New York University Stimulation, production and culturing of hematopoietic progenitor cells by fibroblast growth factors
US5981165A (en) * 1991-07-08 1999-11-09 Neurospheres Holdings Ltd. In vitro induction of dopaminergic cells
US5750376A (en) * 1991-07-08 1998-05-12 Neurospheres Holdings Ltd. In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
WO1994003199A1 (en) * 1992-08-04 1994-02-17 Regeneron Pharmaceuticals, Inc. Method of enhancing differentiation and survival of neuronal precursor cells
NZ282999A (en) * 1994-03-07 1997-12-19 Immunex Corp Extracorporeal cell culture and transplantation kit
CA2249596C (en) * 1996-03-22 2011-11-08 Creative Biomolecules, Inc. Methods for enhancing functional recovery following central nervous system ischemia or trauma
US20020136705A1 (en) * 1998-06-30 2002-09-26 Jonathan Dinsmore Porcine spinal cord cells and their use in spinal cord repair
CA2373808C (en) * 1999-05-14 2011-04-19 Henry Ford Health System Bone marrow transplantation for treatment of central nervous system damage

Also Published As

Publication number Publication date
MXPA02001719A (es) 2003-09-25
CN1753686A (zh) 2006-03-29
JP2003507349A (ja) 2003-02-25
CA2380953A1 (en) 2001-02-22
IL148175A0 (en) 2002-09-12
AU6790300A (en) 2001-03-13
WO2001012236A9 (en) 2002-09-06
BR0013388A (pt) 2002-08-27
EP1210106A2 (en) 2002-06-05
WO2001012236A3 (en) 2001-08-30
WO2001012236A2 (en) 2001-02-22
NO20020779D0 (no) 2002-02-15

Similar Documents

Publication Publication Date Title
NO20020779L (no) Fremgangsmåter, preparater og sett for å fremme helbredelse ved skader på sentralnervesystemet
NO20024577D0 (no) Fremgangsmåte for behandling ved å bruke ligand-immunogene konjungater
DK1076657T3 (da) Hidtil ukendte hydroxyindoler, deres anvendelse som inhibitorer for phosphodiesterase 4 og fremgangsmåde til deres fremstilling
NO20016114L (no) Preparater og fremgangsmåter for å öke kolesterolutströmming og heve HDL ved anvendelse av ATP-bindingskassett-transportörprotein ABC1
AU1449401A (en) Method using prior activities to improve the completion of transaction
NO20031218L (no) Kombinasjonsterapi for behandling av autoimmunsykdommer ved anvendelse av B-cellereduserende immunregulerende antistoff kombinasjon
NO20002796L (no) Kombinert fremgangsmåte for forbedret hydrogenbehandling av dieseldrivstoffer
NO20001870D0 (no) Ny fremgangsmõte for behandling
AU2000260550A1 (en) Treatment of skin damage using polyenylphosphatidylcholine
AU1811301A (en) Methods for removal, purification, and concentration of viruses, and methods of therapy based thereupon
EA200000274A3 (ru) Способы получения и промежуточные соединения для получения противораковых соединений
ID30276A (id) Metode untuk mengobati gangguan-gangguan seksual
AU2002360544A1 (en) Methods and system for adding liquidity to alternative investment transactions
NO20013770D0 (no) Metoder og blandinger for å öke antall hvite blodceller
AU3998400A (en) Methods of treating c1s-mediated diseases and conditions, and compounds and compositions therefor
IS6521A (is) Aðferð til að hreinsa gerjunarseyði
IS6575A (is) Hýdroxýfenýl-píperidín-4-ýlíden-metýl-bensamíðafleiður til að meðhöndla sársauka
DK0950657T3 (da) Substituerede carbazoler, fremgangsmåde til deres fremstilling og deres anvendelse som sPLA2-inhibitorer
AU2002210462A1 (en) Transdermal therapeutic system for treating restless-legs-syndrome
NO20026222L (no) Fremgangsmåte til å behandle neutrofilrelaterte sykdommer med topiske anestesimidler
NO20022834D0 (no) Zeolitt SSZ-50, fremgangsmåte for fremstilling og anvendelse av denne
EE200200632A (et) Glükokortikoidravimeid sisaldavad preparaadid bronhopulmonaalsete haiguste raviks
IS6563A (is) Hýdroxýfenýl-píperasinýl-metýl-bensamíðafleiður til að meðhöndla sársauka
NO20006117D0 (no) Aza-heterosykliske forbindelser anvendt for å behandle neurologiske sykdommer og hårtap
NO20021947L (no) Bio-b¶rende matrikser, fremgangsmåte for fremstilling og anvendelse derav

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application